Evidence map›Paper›PMID 31338502›Full record

ReviewLab on a chip2019

Microfluidic epigenomic mapping technologies for precision medicine.

Chengyu Deng, Lynette B Naler, Chang Lu

Abstract readReview
In one paragraph

Review in Lab on a chip, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Microfluidic Nanoparticle Separation for Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  2. Omics Technologies in Veterinary Medicine: Literature Review and Perspectives in Transfusion Medicine.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chengyu DengDepartment of Chemical Engineering, Virginia Tech, Blacksburg, Virginia 24061, USA. changlu@vt.edu.
Lynette B NalerDepartment of Chemical Engineering, Virginia Tech, Blacksburg, Virginia 24061, USA. changlu@vt.edu.ORCID 0000-0002-1336-3236
Chang LuDepartment of Chemical Engineering, Virginia Tech, Blacksburg, Virginia 24061, USA. changlu@vt.edu.ORCID 0000-0003-0181-5888

Funding

Probing dynamics in protein-DNA interactions during disease development using sinR01EB017235 · NIBIB · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LU, CHANG · 2014 to 2017
$1.3M
Next-generation MOWChIP-seq for high-throughput epigenomic profiling using clinically relevant samplesR33CA214176 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LU, CHANG · 2017 to 2019
$1.2M
Drop-BS: high-throughput single-cell bisulfite sequencing on a microfluidic droplet platformR21HG010195 · NHGRI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LU, CHANG · 2018 to 2020
$624k
Ultrasensitive microfluidic ChIP-MethylC-seq for integrative analysis of histone modification and DNA methylationR21HG009256 · NHGRI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LU, CHANG · 2016 to 2018
$604k
NCI NIH HHS R33 CA214176NHGRI NIH HHS R21 HG009256NHGRI NIH HHS R21 HG010195NIBIB NIH HHS R01 EB017235
6 · The paper itself

Abstract

Epigenomic mapping of tissue samples generates critical insights into genome-wide regulations of gene activities and expressions during normal development and disease processes. Epigenomic profiling using a low number of cells produced by patient and mouse samples presents new challenges to biotechnologists. In this review, we first discuss the rationale and premise behind profiling epigenomes for precision medicine. We then examine the existing literature on applying microfluidics to facilitate low-input and high-throughput epigenomic profiling, with emphasis on technologies enabling interfacing with next-generation sequencing. We detail assays on studies of histone modifications, DNA methylation, 3D chromatin structures and non-coding RNAs. Finally, we discuss what the future may hold in terms of method development and translational potential.

Indexed as

EpigenomicsMicrofluidic Analytical TechniquesPrecision MedicineAnimalsHumans

Identifiers

PMID31338502
PMCPMC6697104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.